In a market where most KOSPI stocks are experiencing sharp declines, Daewon Pharmaceutical is seeing a significant rise. This surge is attributed to optimism surrounding the development of a next-generation obesity treatment.
As of 2:10 PM on June 8, Daewon Pharmaceutical shares were trading at 13,450 won, up 2,210 won (19.66%) from the previous trading day. The stock had already reached its daily limit on June 5 and is now approaching a 20% increase.
The strong performance is believed to be driven by heightened investor interest ahead of the announcement of research results for the company's obesity treatment candidate.
Daewon Pharmaceutical previously announced that it would present preclinical research results for its quadruple-action obesity treatment candidate at the American Diabetes Association (ADA 2026) conference in New Orleans on June 4. The company plans to showcase its proprietary multi-action design technology and differentiated receptor activity indicators, along with detailed data on weight loss, changes in food intake, and blood sugar improvement confirmed through animal experiments.
This candidate combines GLP-1, GIP, and glucagon receptors with a gastrin mechanism. Gastrin is a hormone that regulates gastric acid secretion and digestive functions, and is known to play a role in protecting pancreatic beta cells and maintaining gastrointestinal function. Industry experts are closely watching whether this candidate can maintain the weight loss effects of existing GLP-1 class obesity treatments while alleviating concerns about potential long-term organ function decline associated with prolonged use.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.